Regulatory Moderna flu vaccine wins unanimous support from FDA panel BioPharma DiveThe endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year.Infectious DiseaseRead full story pharminent June 18, 2026 (Last updated: June 19, 2026) BioPharma Dive The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: MSD takes on Pfizer’s Prevnar with new Capvaxive approvalNext: FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
